A Phase I, First‐in‐Human Study of GSK2849330, an Anti‐HER3 Monoclonal Antibody, in HER3‐Expressing Solid Tumors

BACKGROUND: GSK2849330, an anti‐HER3 monoclonal antibody that blocks HER3/Neuregulin 1 (NRG1) signaling in cancer cells, is engineered for enhanced antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity. This phase I, first‐in‐human, open‐label study assessed the safety, phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Gan, Hui K., Millward, Michael, Jalving, Mathilde, Garrido‐Laguna, Ignacio, Lickliter, Jason D., Schellens, Jan H.M., Lolkema, Martijn P., Van Herpen, Carla L.M., Hug, Bruce, Tang, Lihua, O'Connor‐Semmes, Robin, Gagnon, Robert, Ellis, Catherine, Ganji, Gopinath, Matheny, Christopher, Drilon, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
New Drug Development and Clinical Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488777/
https://www.ncbi.nlm.nih.gov/pubmed/34132450
http://dx.doi.org/10.1002/onco.13860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488777/
https://www.ncbi.nlm.nih.gov/pubmed/34132450
http://dx.doi.org/10.1002/onco.13860

Ejemplares similares